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In vivo label-free structural and 
biochemical imaging of coronary 
arteries using an integrated 
ultrasound and multispectral 
fluorescence lifetime catheter 
system
Julien Bec  1, Jennifer E. Phipps1, Dimitris Gorpas  1,4, Dinglong Ma1, Hussain Fatakdawala  1,5, 
Kenneth B. Margulies2, Jeffrey A. Southard3 & Laura Marcu1
Existing clinical intravascular imaging modalities are not capable of accurate detection of critical 
plaque pathophysiology in the coronary arteries. This study reports the first intravascular catheter 
combining intravascular ultrasound (IVUS) with multispectral fluorescence lifetime imaging (FLIm) that 
enables label-free simultaneous assessment of morphological and biochemical features of coronary 
vessels in vivo. A 3.7 Fr catheter with a fiber-optic channel was constructed based on a 40 MHz clinical 
IVUS catheter. The ability to safely acquire co-registered FLIm-IVUS data in vivo using Dextran40 
solution flushing was demonstrated in swine coronary arteries. FLIm parameters from the arterial wall 
were consistent with the emission of fluorophores present in healthy arterial wall (collagen, elastin). 
Additionally, structural and biochemical features from atherosclerotic lesions were acquired in ex vivo 
human coronary samples and corroborated with histological findings. Current results show that FLIm 
parameters linked to the amount of structural proteins (e.g. collagen, elastin) and lipids (e.g. foam cells, 
extracellular lipids) in the first 200 μm of the intima provide important biochemical information that can 
supplement IVUS data for a comprehensive assessment of plaques pathophysiology. The unique FLIm-
IVUS system evaluated here has the potential to provide a comprehensive insight into atherosclerotic 
lesion formation, diagnostics and response to therapy.
Myocardial infarction due to plaque rupture is a leading cause of sudden cardiac death1. Due to positive remod-
eling, high plaque burden may occur without significant stenosis, and therefore cannot be reliably identified 
using conventional angiography. Intravascular ultrasound (IVUS) enables identification of plaque burden due to 
its high penetration depth (up to 10 mm2) but lacks the spatial resolution to identify small scale features such as 
details of the intima3, or biochemical changes linked with atherosclerotic lesion formation and evolution. Optical 
coherence tomography (OCT) provides improved spatial resolution (<20 µm2) that enables highly detailed vis-
ualization of fibrous cap and intima morphology as well as some level of detection of macrophages4 at the cost 
of penetration depth, thus limiting the ability to assess plaque burden. Direct access to biochemical information 
could prove valuable for the study of atherosclerotic lesion pathophysiology. Previous studies showed that spec-
troscopic techniques including near infrared (NIR)5, 6, Raman7 and fluorescence8, 9 have the potential to provide 
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biochemical information. Thus there is a growing interest in developing “orthogonal” multimodal techniques 
combining biochemical and structural imaging capabilities10, 11, which is the focus of this study.
Previous studies have demonstrated that fluorescence lifetime techniques based on UV- light induced tissue 
autofluorescence12, 13 can complement IVUS to better identify distinct coronary plaque pathologies. In previous 
work, we developed a catheter with a small cross-section profile (3.2 Fr) relying on sequential scanning of the 
field of view by independent FLIm and IVUS imaging cores integrated into a single sheath and imaging section14. 
The catheter was then used to interrogate ex vivo human coronary arteries. The study showed that this label-free 
technique combining IVUS and FLIm can differentiate between 8 different plaque subtypes, identifying for exam-
ple thin cap fibroatheroma (TCFA) with 90% sensitivity and 100% specificity using pathological features such 
as the presence of macrophages in the fibrous cap. Thus, this bi-modal technique is suitable for identification 
of plaque phenotypes known to be responsible for acute coronary syndromes. However, the embodiment of the 
FLIm-IVUS catheter technology used in this previous work was not suitable for in vivo use, as the device was 
not flexible enough and the sequential scanning scheme limited the ability to co-register data in the presence 
of motion. Additionally, in vivo coronary imaging requires displacement of blood with an optically transparent 
solution.
We demonstrate here how we successfully addressed these challenges by integrating IVUS and FLIm ele-
ments into a compact, single rotational intravascular catheter (3.7 Fr) able to simultaneously acquire co-registered 
structural (via IVUS) and biochemical (via FLIm) images of coronary arteries in vivo in a single pull-back. The 
technical performance of the bi-modal system assessed with artery phantoms. The ability of the system to acquire 
robust bi-modal data in coronary arteries in vivo using standard percutaneous coronary intervention techniques 
in combination with a Dextran solution bolus flush was demonstrated in healthy swine. Imaging of a few repre-
sentative diseased human samples was performed and showed that different types of lesions in diseased coronary 
arteries, identified via histology, are characterized by FLIm biochemical signatures consistent with findings from 
earlier studies.
New imaging techniques for evaluation of plaque pathophysiology are of great interest to both improve the 
understanding of mechanisms driving plaque formation as well as support the development of new preventative, 
pharmaceutical and interventional therapies10. By providing this information, the presented device could become 
a valuable addition to the field of cardiovascular imaging.
Results
FLIm-IVUS imaging catheter system. The bi-modal imaging system was developed based on a Boston 
Scientific iLab™ IVUS system and is composed of a custom IVUS/FLIm rotational catheter, a modified Boston 
Scientific motor drive unit (MDU), and data acquisition and display units of both IVUS and FLIm sub-systems 
(Fig. 1).
Figure 1. System overview. The system, able to display IVUS images in real time using the clinical interface, 
is composed of a 3.7 Fr IVUS/FLIm catheter, an IVUS motor drive unit (MDU) modified to accommodate 
an optical channel, connected to a wavelength selection module (WSM). The WSM enables both coupling of 
the pulsed excitation light and spectral decomposition of the collected fluorescence signal. The signal from 
each band is sent to the photomultiplier tube (PMT) using different lengths of optical delay lines that enables 
measurement over four wavebands using a single detector. When acquiring bimodal data, co-registration is 
insured by sampling both FLIm and IVUS signal with a single digitizer.
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The size (3.7 Fr) of the FLIm/IVUS catheter reported here is compatible with coronary imaging. In its cur-
rent configuration, the IVUS performance (central frequency and bandwidth) is similar to the standard 40 MHz 
OptiCross catheter. The modified MDU provided a robust interface with the catheter, with optical coupling losses 
of less than 1 dB through the MDU.
The system enables scans of a 20 mm section of vessel in 5 seconds with a rotation speed of 1800 rpm, pro-
viding 25000 independent multispectral fluorescence lifetime point measurements of the vessel surface (20 kHz 
laser repetition rate, 4 time average per point), co-registered with IVUS data. The data analysis software allows 
for display of the intensity en face images derived from FLIm within seconds following the scan and the fast data 
processing based on Laguerre technique enables the computation and display of lifetime maps from all 4 spectral 
channels in less than 2 minutes following the end of the scan.
In vivo FLIm/IVUS imaging of healthy coronary arteries. The ability of the bi-modal imaging system 
to access coronary arteries, flush the blood from the field of view and acquire robust autofluorescence data in vivo 
was evaluated in two swines. The characterization was focused on the following: (i) ability of the catheter to access 
tortuous anatomy, (ii) ability to flush blood from the field of view, (iii) ability to image a range of vessel diameters, 
and (iv) ability to discriminate targets based on lifetime and spectral information.
Swine data obtained from a co-registered FLIm/IVUS acquisition performed in vivo in a 3 mm diameter section 
of the circumflex artery using a 5 cc/s flushing rate are presented in Fig. 2. Strong fluorescence emission was recorded 
in channels 1 and 2 (Fig. 2a), whereas emission is low in channel 3 and absent in channel 4, matching the emission of 
collagen and elastin (see supplemental material). A map of the probe-to-vessel wall distance (Fig. 2b) was extracted 
from IVUS data and used to correct for the effect of probe-to-wall distance on the intensity data (Fig. 2c). We 
observe the guidewire shadow as well as low intensity areas centered on the green dotted line shown in Fig. 2c. A 
longitudinal section across this line (Fig. 2d) shows that the catheter is in contact with the wall in these areas. In this 
Figure 2. Ability to acquire co-registered FLIm/IVUS data in vivo in coronary arteries was evaluated in swine. 
Intensity en face image of a section of left circumflex artery acquired in vivo in pig (a). A distance map derived 
from IVUS (b) enables distance correction of the intensity image (c). For each of the four channels, a lifetime 
image is derived (e). Channel 2 presents the most fluorescence due to presence of collagen and elastin and 
shows very uniform background as expected from a healthy pig (f). The FLIm data can be combined with IVUS 
to provide bimodal 3D renderings (g) as well as sections of the vessel (d) (30° orientation, corresponds to the 
dashed line of panel c).
www.nature.com/scientificreports/
4SCientifiC REPORTS | 7: 8960  | DOI:10.1038/s41598-017-08056-0
configuration, blood can be trapped between the device and the vessel wall: the increased absorption of light from 
blood in both excitation and autofluorescence emission wavelengths creates these low intensity areas.
Fluorescence lifetime is an inherently ratiometric technique and presents the ability to extract lifetime values 
independent from intensity for all but the lowest measured fluorescence signal (typically SNR > 15 dB, as reported 
previously15). This property is verified by computing lifetime maps retrieved from each channel (Fig. 2e,f). 
After excluding the guidewire location, we verified that recovered lifetime values were uniform across the field 
of view as expected from a healthy artery. The recovered values for this 3 mm diameter vessel were as follows 
4.98 ± 0.20 ns (channel 1), 5.19 ± 0.12 ns (channel 2), 4.55 ± 0.29 ns (channel 3), and no significant emission in 
channel 4. This was achieved in spite of wide variations of intensity over the field of view and noticeable signal 
absorption by blood in some areas, as described above. The independence of the lifetime information from signal 
intensity is further presented in the supplemental material. 3D rendering of the fluorescence lifetime image was 
also created to enable easy co-location of FLIm and IVUS features (Fig. 2g).
The ability of the catheter system to differentiate targets based on FLIm information (lifetime, spectra) was 
evaluated by acquiring multimodal data in a stented section as presented in Fig. 3. Fluorescence targets were 
painted on the stent (Fig. 3a) to provide contrast with respect to the vessel wall autofluorescence. Intensity 
weighted lifetime maps, where the color represents the lifetime value and the brightness represents the amount of 
signal, are displayed for each channel (Fig. 3c). As presented in the normalized emission spectra of both markers 
(Fig. 3b), the marker M1 emission is overlapping with the vessel autofluorescence emission in channels 1 and 2, 
but can be readily identified in these channels due to its shorter lifetime (~3.3 ns). Additional discrimination is 
provided by the spectral information: the peak emissions of markers M1 and M2 in channels 3 and 4 respectively 
provide clear identification of the location of the markers. The 3D rendering (Fig. 3d) obtained by combining 
FLIm and IVUS information illustrates how areas of interest identified using FLIm data can be localized within 
the vessel morphology representation.
Imaging large vessels presents challenges for fluorescence signal acquisition as the excitation collection effi-
ciency decreases with probe-to-wall distance. When imaging a 5 mm diameter section of vessel, the collected flu-
orescence signal in the region of interest farthest from the probe was reduced by 14.5 dB with respect to the area 
reported for the 3 mm vessel. For this second region, the recovered lifetime values (e. g. 5.14 ± 0.33 ns in channel 
2) were comparable with those obtained for smaller vessels (5.19 ± 0.12 ns in channel 2), and ensure that the 
system can collect data for all vessel diameters expected during coronary intervention. To evaluate the flushing 
parameters, the flushing flow was varied between 2 cc/s and 8 cc/s. While flushing flow below 4 cc/s did not lead to 
proper clearing of the blood from the field of view, no noticeable difference in flushing efficiency were identified 
for both smaller and larger vessel between 4, 6 and 8 cc/s flushing rates.
Ex vivo plaque characterization using FLIm and IVUS data. We present results from two represent-
ative cases chosen from human coronary arteries imaged ex vivo to illustrate the typical contrast provided by 
FLIm in diseased vessels. We will also use this data to illustrate how FLIm-derived compositional features can 
complement the IVUS-derived morphological features (e.g. lumen geometry, plaque thickness and presence of 
calcifications) enabling a more comprehensive evaluation of plaque pathophysiology, The cases consist of data-
sets of co-registered IVUS and multispectral FLIm from 20 mm-long arterial segments, with matching histology 
Figure 3. The ability of FLIm to resolve targets using fluorescence lifetime and spectral contrast was evaluated 
in vivo in swine coronary arteries. In vivo images of stented section of swine circumflex artery. Fluorescent 
markers M1 & M2 are painted onto the stent to provide fluorescence contrast (a), present broad emission 
spectra (b). M1 emission presents a short (~3 ns) lifetime and can be easily discriminated from healthy vessel 
background (~5.3 ns) in channels 1 and 2. M2 has weaker emission in channels 1 and 2 but is readily identified 
in channel 4 (c). The ability to resolve fluorescent features based on both spectral and temporal parameters 
makes FLIm a powerful technique to discriminate areas of interest. Combining FLIm and IVUS images enables 
3D rendering (d).
www.nature.com/scientificreports/
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sections. The use of a dedicated sample holder during imaging enables the accurate co-registration of the imaging 
data with histology sections. One example is presented in Fig. 4. Results from a second artery are presented in the 
supplemental materials (Figs s6 and s7).
Ability of FLIm to resolve distinct cap compositions. The FLIm data are represented using spectral 
ratio-weighted lifetime maps, projected onto the vessel lumen segmented from the IVUS data (Fig. 4a). This rep-
resentation enables both time-resolved and spectral information to be included in the same graphic representa-
tion: the lifetime measured in each of the four channels of the instrument is color-coded (see Fig. 4e), whereas 
Figure 4. FLIm biochemical information supplements IVUS for the assessment of atherosclerotic lesion 
pathophysiology. Spectral ratio weighted lifetime images map the measured lifetime (color), as well as relative 
strength of the signal (brightness) for channels 1 (Collagen), 2 (Elastin, some collagen and lipids) and 3 
(lipids, ceroid and lipofuscine) of the instrument. Section 1 presents a fibrocalcified lesion. Areas of superficial 
calcification (3 to 9 o’clock) present less fluorescence from collagen (channel 1) than the rest of the vessel. 
Section 2 presents diffuse intimal thickening (DIT, upper quadrant) as well as a fibrotic lesion with a deeper 
necrotic core (lower quadrant), easily identifiable in the IVUS cross section. The increased presence of collagen 
in the fibrotic area corresponds to high fluorescence intensity in channel 1. Infiltration of punctate foam cells 
(FC) in the lower right quadrant (see CD68) corresponds to increased lifetime in channel 2 and some low level 
fluorescence in channel 3. Section 3 presents a thin cap fibroatheroma (TCFA) in the lower right quadrant. 
The fluorescence signature of this area is characterized by an absence of channel 1 signal (no collagen) and 
long lifetime in channels 2 and 3 with a maximum emission in channel 3 (large amounts of lipids/ceroid/
lipofuscine). Other locations in the section present a signature expected from DIT/fibrotic lesions (collagen/
elastin). Calcification from 6–9 o’clock is readily detected by IVUS. Section 4 presents DIT (top, left) and a 
fibrotic lesion (bottom, right). The fibrotic area can be differentiated from DIT by its higher collagen content 
(increased channel 1 intensity, longer channel 2 lifetime). The absence of infiltrated FC (see CD68) in this 
fibrotic area is consistent with the much lower lifetime observed here with respect to the fibrotic region in 
section 1. Proteoglycans, identified by the alcian blue color in the 6 to 8 o’clock region of the Movat’s section may 
explain the increase in lifetime observed at this location in the channel 1 image. En face images of lifetime (e) 
and intensity ratio (f) used to compute ratio weighted lifetime images shown in (a).
www.nature.com/scientificreports/
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each pixel’s brightness is weighted by the share of the total measured fluorescence intensity originating from 
this specific channel, or intensity ratio, represented in Fig. 4f (See supplemental methods section for additional 
details). These maps are independent from variations in excitation/collection efficiency due to distance and geom-
etry and reflect intrinsic fluorescence properties of the superficial layer of the arterial wall (~200–300 µm16). These 
data are then compared with histology sections stained with Movat’s pentachrome (Fig. 4c) and CD68 (Fig. 4d) 
obtained from four different axial locations.
Section 1 presents a fibrocalcified lesion. The upper region (9 to 3 o’clock) presents strong signal from colla-
gen, as expected from a fibrous lesion. Calcified areas at the luminal surface (3 to 9 o’clock), easily identified from 
IVUS data and confirmed on H&E section (not shown) are characterized by a low fluorescence contribution 
from collagen (channel 1). Section 2 presents diffuse intimal thickening (DIT) in the upper quadrant as well as 
a fibrotic lesion with a deeper necrotic core (lower quadrant), easily identifiable in the IVUS cross section. The 
strong presence of collagen in the fibrotic area matches the high fluorescence intensity in channel 1. Infiltration 
of punctate foam cells (FC) in the lower right quadrant (See Fig. 4d, CD68) corresponds to increased lifetime 
in channel 2 ( > 5.5 ns) and presence of some fluorescence in channel 3. Section 3 presents a clear instance of 
thin cap fibroatheroma (TCFA) in the lower right quadrant. The fluorescence signature of this area is charac-
terized by an absence of channel 1 signal (low collagen content) and long lifetime in channels 2 (>6.5 ns) and 3 
(>7.5 ns) with a maximum emission in channel 3. This large increase of lifetime may be linked to a change in the 
lipid composition observed in advanced lesions17–19. Other locations in the section present a signature expected 
from DIT/fibrotic lesions (collagen/elastin). Calcification from 6–9 o’clock is readily detected by IVUS. Section 
4 presents DIT (top, left) and a fibrotic lesion (bottom, right). The fibrotic area can be differentiated from DIT by 
its higher collagen content (increased channel 1 intensity, longer channel 2 lifetime). In this fibrotic location, no 
infiltrated FC are visible (see Fig. 4d, CD68). This is consistent with the lifetime signature, characteristic of colla-
gen/elastin emission and much lower than values from the fibrotic region in section 2 where foam cell infiltration 
was observed. The presence of proteoglycans is identified by the alcian blue color in the 6 to 8 o’clock region of 
the Movat’s section. Reported fluorescence properties20 are consistent with the increase in lifetime and intensity 
observed at this location in the channel 1 image.
The ability of FLIm to provide contrast based on both spectral and temporal information enables the delinea-
tion of various areas based on FLIm signature. While the exact source of molecular contrast is difficult to confirm 
with certainty (emission spectra of various compounds overlap and may contribute to the overall fluorescence 
signatures) the areas delineated by FLIm match well with specific plaque compositional features identified from 
histology.
Ability to resolve morphology. IVUS is well known for its ability to resolve vessel morphology, including 
lumen shape and plaque burden, due to its large penetration depth. As expected, the overall vessel shape (lumen 
geometry, intima thickness) observed from the acquired IVUS B-scans is very similar to the vessel geometry iden-
tified in histology sections of the corresponding axial locations; this provides a convenient way to independently 
verify the accuracy of imaging/histology registration. Additionally, the presence of calcification is easily identified 
in both IVUS and Movat’s pentachrome sections (see Fig. 4, 2nd section, lower left quadrant) and also provides a 
clear landmark that can be used to further assess registration.
Discussion
This study demonstrates for the first time that IVUS and FLIm imaging techniques can be integrated into a sin-
gle catheter to acquire co-registered structural and biochemical information in vivo in swine coronary arteries, 
without the need for exogenous contrast agents. Integration of both imaging modalities was achieved so that the 
performance of the clinical IVUS component was not negatively impacted by the addition of FLIm capability. 
More specifically, the current catheter design could access coronary arteries using standard percutaneous coro-
nary intervention techniques in conditions representative of clinical use. We note that while in its current con-
figuration, the image acquisition speed of the FLIm-IVUS system is limited by the framerate of the clinical IVUS 
from which it derives, in turn limiting the pullback length for a 5 s bolus flush to 20 mm, the main limitation of the 
current system The FLIm instrumentation employed enables point measurements frequencies of up to 100 KHz, 
corresponding to 150 frames per second (fps), compared to 30 fps of the clinical IVUS. This constraint is shared 
with combined IVUS-OCT and is the object of further investigation21. A general trend towards increased framer-
ate for the next generation of clinical IVUS22 will be leveraged to build a faster FLIm/IVUS system.
Use of Dextran 40 solution to flush blood from the field of view enabled the collection of bi-modality data. 
Low molecular weight dextran solution has high optical transparency for UV light and is a cost efficient alterna-
tive to iodinated contrast23, 24 for intravascular OCT imaging. The flushing parameters (typically 4–5 cc/s and less 
than 40 mL per sequence) are compatible with clinical use. We demonstrated that the FLIm signal acquired in 
these experimental conditions is robust and enables differentiation of fluorescent features based on both emission 
spectra and lifetime differences, for vessels up to 5 mm in diameter, therefore covering the whole range of vessel 
lumen size expected in patients. The standard deviation of the recovered lifetime (0.1–0.3 ns range) is much lower 
than the fluorescence contrast observed between different lesions present in human samples (1–4 ns). We posit 
that the proposed device should therefore have the ability to discriminate plaque features in vivo.
The combination of FLIm with a morphological imaging modality such as IVUS is important, because FLIm 
alone cannot provide morphometric information about lumen size, geometry or direct measurement of lesion 
size. When projected onto the vessel lumen boundary identified by IVUS, the dimensions of FLIm features can 
be precisely assessed.
Data was acquired from a limited number of ex vivo diseased human arteries. The fluorescence signature of 
various lesions is consistent with findings from earlier studies from our group12, 13. Based on this information, we 
showed that FLIm complements the well-documented ability of IVUS to identify lumen size, plaque burden and 
www.nature.com/scientificreports/
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calcification. FLIm provides biochemical details about the composition of the vessel wall and allows straightfor-
ward identification of fibrotic plaque or ThCFA through the detection of an increase in collagen and a decrease of 
elastin content in the superficial layer of the intima25. TCFA, characterized by a decrease of elastin and collagen 
content and the presence of lipids and lipoproteins in the superficial layers of the intima could also be identified 
using changes in fluorescence signature, distinct from both diffuse intimal thickening and fibrotic plaques. The 
signal detected in channel 3 did not correspond to any of the pure compounds tested independently (supple-
mental materials, Fig. s4) but suggests the presence of fluorophores such as ceroid26 and lipofuscin27, which both 
have emission spectra consistent with the measured signals and are linked with the activity of inflammatory cells. 
Additionally, the contribution of proteoglycans to fibrotic plaque autofluorescence may be identifiable. These 
preliminary findings are very encouraging to support the claim that multispectral FLIm based on UV excitation 
of tissue autofluorescence is well suited to the intravascular identification of various biochemical species relevant 
to the study of plaque pathophysiology. In summary, the fluorescence signature observed for different plaque 
subtypes (across all 20 samples imaged in this study) was in good agreement with fluorescence properties of 
biochemical/morphological features, as confirmed by histology. Current results support further interrogation of 
a large number of coronary samples and studies designed to demonstrate statistical differences between distinct 
subtypes.
Although the proposed method does not provide the depth of the identified biochemical species, the penetra-
tion depth of the UV light used for excitation (~200 µm16) provides a sectioning effect by limiting the interrogated 
volume to the superficial layer, known to be of particular relevance to plaque characterization3.
Vascular imaging can be performed using both invasive (catheter based) and non-invasive techniques. 
Non-invasive methods provide obvious benefits by preventing the risks associated with PCI and potentially ena-
bling screening of patients. Such modalities now go beyond angiography and include magnetic resonance angiog-
raphy (MRA), Coronary Computed Tomographic Angiography (CCTA) as well as functional imaging modalities 
such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) sup-
ported by the development of molecular probes targeting inflammation, hypoxia or calcifications28. The ability of 
CCTA and MRA to evaluate calcifications29 and plaque thickness30 in coronary arteries has been documented but 
non-invasive imaging of atherosclerosis in coronary arteries is hampered by radiation exposure for PET/SPECT 
and CT, limited spatial resolution and image quality as well as motion artifacts28 and will require significant 
technological improvements before potentially replacing intravascular imaging methods. In contrast to CCTA 
or MRA, IVUS has been able for 20 years to provide clinicians with detailed morphological information about 
coronary plaque but stenosis and plaque burden alone are poor predictors of acute coronary syndrome31. In spite 
of improvement in spatial resolution provided by OCT in comparison to IVUS, it is also unlikely that morpho-
logical information alone will enable identification of rupture-prone plaque32. Catheter-based near infrared spec-
troscopy (NIRS)-ultrasound, now available for clinical use, provides clinicians with “chemograms” that display 
the presence of lipid in the vessel wall. However, the absence of depth resolution, combined with a relatively high 
penetration depth (multiple millimeters), may lead to ambiguous information with respect to volume or localiza-
tion of these lipids, thus limiting the clinical value of the information. Molecular imaging methods such as near 
infrared fluorescence (NIRF), implemented at the research level in NIRF-OCT multimodal approaches aim to 
identify lipid-rich and inflamed plaque using both exogenous markers33, 34 and label free approaches35. The ability 
of NIRF-OCT to detect inflammation has promising potential. Nonetheless, these modalities lack the ability to 
assess the presence and potential degradation of structural proteins such as collagen and elastin. In contrast, the 
bi-modal FLIm-IVUS system reported here is able to evaluate and characterize plaque based on the presence of 
structural proteins such as collagen and elastin as well as peroxidized lipid-protein complex (ceroid) and foam 
cells near the surface of the lumen. Combined with the well documented ability of IVUS to evaluate lumen shape, 
plaque burden and calcification, this instrument provides an exciting option for the in vivo study and detection 
of various plaque subtypes.
This new approach may benefit both patients and researchers alike. Enabling in vivo evaluation of plaque 
type may improve understanding of plaque physiopathology and mechanisms of disruption. In addition, the 
effect of therapeutic agents on biochemical and structural composition of plaque could be evaluated, leading to a 
non-invasive method to monitor efforts aimed at acute coronary syndromes prevention.
Methods
Integrated FLIm/IVUS system. FLIm is based on a fast pulse sampling technique previously developed by 
our group36. Pulses of UV-light (355 nm, 20 kHz) are sent to the sample and generate fluorescence emission from 
the arterial wall that results from the autofluorescence of structural proteins (collagen, elastin), as well as lipids 
and lipoproteins. The UV pulses were delivered to the arterial wall using a fiber optic. The generated autofluores-
cence signal was collected using the same fiber and spectrally resolved in four distinct wavelength bands: Channel 
1 (390 nm), Channel 2 (450 nm), Channel 3 (540 nm) and Channel 4 (630 nm). The correspondence between 
channels and key fluorophores is presented in Table 1 of the supplemental methods. FLIm imaging capability 
was integrated into the existing IVUS system by modifying the IVUS MDU to accommodate an optical channel 
and developing a custom 3.7 Fr monorail bi-modal imaging catheter (Fig. 1). The system is able to display IVUS 
information in real time using the standard user interface and provides guidance to identify areas of interest, as 
well as co-registered FLIm/IVUS images as demonstrated in phantom (see supplemental material).
Data were processed to make optimal use of the ability of the system to differentiate biochemical compounds 
using fluorescence decay characteristics as well as spectral intensities: for each channel, fluorescence lifetime and 
intensity ratio maps were created. Additional information about data processing is available in the supplemental 
methods.
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In vivo coronary imaging in swine. This study was conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals37. The Institutional Animal Care and Use Committee at the University of 
California, Davis approved the study for the use of Yorkshire cross swine. Animal care and use was performed 
by qualified individuals and supervised by veterinarians. All facilities and transportation complied with current 
legal requirements and guidelines. Anesthesia was used in all surgical interventions. Our animal facilities meet 
the standards of the American Association for Accreditation of Laboratory Animal Care.
The pigs, in the 60–70 kg range, were subject to general anesthesia and the bi-modal catheter device was intro-
duced into the left circumflex coronary under fluoroscopy guidance through a standard 7 French guiding catheter 
over a 0.014 inch guidewire. Detail of the protocol can be found in the supplemental materials.
In the first animal, an initial set of bi-modal pull-back scans (n = 10) was acquired in vessel diameters ranging 
from 1.5 mm to 3.5 mm using non-occlusive flush (4 to 8 cc/s for 10 s) of low molecular weight Dextran solution 
(10% LMD in 5% Dextrose, Hospira, IL) to remove blood from the field of view. The 2.75 mm stent (Promus, 
Boston Scientific, MA) with fluorescent markers (Scribbles, Duncan, Fresno, CA) was then placed in the circum-
flex coronary artery. The stented area, where lifetime and spectral emission contrast between markers and healthy 
vessel wall is expected, was subsequently imaged with the IVUS/FLIm catheter. In the second animal, a similar 
procedure was adopted: images were acquired in vessels with diameters ranging from 3 mm to 5 mm using flush-
ing flow rates between 2 cc/s and 8 cc/s to confirm the results from the first animal and evaluate a wider range of 
vessel sizes.
Ex vivo human coronary imaging. The arteries (n = 21) were provided by the University of Pennsylvania 
heart transplant program. Whole human hearts were procured from two separate patient groups: non-failing 
brain dead organ donors with no overt history of heart failure, and end stage heart failure transplant patients. 
No organs were procured from prisoners. All hearts received in situ cold cardioplegia and were placed on wet 
ice in 4 degree Krebs-Henseleit Buffer. Artery samples were removed and snap frozen in liquid nitrogen and 
stored at minus 80 °C. Arteries were de-identified prior to shipping from University of Pennsylvania to UC 
Davis. The study complies with current legal requirements and guidelines and was approved by the University of 
Pennsylvania Hospital Institutional Review Board as well as UC Davis Biological Use Authorization. Prospective 
informed consent for research use of heart tissue was obtained from all transplant recipients and next-of-kin in 
the case of organ donors.
Samples were mounted on a dedicated holder and immersed in 37 °C Phosphate buffered saline (PBS) solu-
tion. PBS was circulated inside the vessel during imaging to maintain lumen shape. Following imaging, the sam-
ples were fixed under perfusion, and sent to the Texas Heart Institute for further processing, sectioning and 
staining. Each artery segment was first cut into rings (~2 mm length). Sections were cut at four different loca-
tions for each ring, leading to at least 32 histology sections per sample. Visualization of plaque morphology 
and composition (collagen, elastin, and lipids) was enabled by H&E and Movat’s pentachrome, correspondingly. 
Immunohistostaining with CD68 was also performed to visualize macrophage content in the vessel wall.
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